We are developing various technologies for the diagnosis and treatment of cancer and blood vessels, which are two major causes of adult death in our country
Products from System Bio-medicinell
Can diagnose cancer with 1 drop of blood
Cancer is the leading cause of death among Japanese. In LSBM, 30,000 genes were measured with DNA chips in liver cancer and stomach cancer, which are known to be common in Japanese, and elucidated the top 100 genes that are increasing in cancer. I am developing a monoclonal antibody to these proteins, and I am developing a technology that can measure these proteins simultaneously with one drop of blood. LSBM is developing a completely new pattern recognition diagnostic method that can reliably diagnose cancer early from patterns of changes in multiple protein concentrations.
Monoclonal antibody that kills cancer cells
SP-3, a monoclonal antibody prepared against a protein that is growing on the cell surface of liver cancer, one of these, has killed cultured hepatic cancer cells and has attracted attention as a candidate for a new hepatic cancer therapeutic drug. LSBM elucidates the molecular target on the cancer cell surface comprehensively, and is rapidly pursuing genomic antibody drug discovery.
Watch arteriosclerosis in test tube
Arteriosclerosis progresses as a silent disease without symptoms and suddenly develops as a myocardial infarction or stroke if the blood vessel becomes clogged. The effect of the medicine is judged in clinical trials where tens of thousands of patients called mega studies participate for many years. LSBM has developed a mixed culture system of 3 dimensional system of many cells and is conducting research to create arteriosclerosis in the test tube. It is now possible to select therapeutic drugs that human beings can hear before entering the mega study in the laboratory, and it is possible to develop innovative pharmaceutical products.
Development of innovative therapeutic drugs from gene network of lipid metabolism and sugar metabolism
Long-term diseases such as cholesterol synthesis inhibitors have been found to act by altering human gene regulation in the long term. Regarding cholesterol and glucose metabolism, we have developed a technology to comprehensively analyze the two major families of Zinc finger protein and G protein coupled receptor, and we are developing innovative new drugs acting on gene networks.